Everolimus
Tocris Bioscience, part of Bio-Techne | Catalog # 6188
mTOR inhibitor; Immunosuppressant
Key Product Details
Description
mTOR inhibitor; Immunosuppressant
Alternative Names
RAD001
Product Description
Everolimus is a mTOR inhibitor. Inhibits tumor proliferation in vitro and in vivo. Inhibits VEGF-induced HUVEC proliferation in vitro, but does not affect tumor vascular permeability in mouse models. Immunosuppressant. Activates autophagy.Product Specifications
Molecular Weight
958.22
Formula
C53H83NO14
Storage
Store at -20°C
Purity
≥98% (HPLC)
Chemical Name
42-O-(2-Hydroxyethyl)rapamycin
CAS Number
159351-69-6
PubChem ID
100926147
InChI Key
HKVAMNSJSFKALM-GKUWKFKPSA-N
SMILES
[H][C@@]12CC[C@H]([C@@](O1)(C(C(N3CCCC[C@]3(C(O[C@@](CC([C@@H](/C=C([C@H]([C@H](C([C@@H](C[C@@H](/C=C/C=C/C=C([C@@H](OC)C2)\C)C)C)=O)OC)O)\C)C)=O)([C@@H](C[C@@H]4CC[C@H]([C@H](OC)C4)OCCO)C)[H])=O)[H])=O)=O)O)C
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 95.82 | 100 | |
| Ethanol | 95.82 | 100 |
Preparing Stock Solutions
for Everolimus
The following data is based on the product molecular weight 958.22
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.04 mL | 5.22 mL | 10.44 mL |
| 5 mM | 0.21 mL | 1.04 mL | 2.09 mL |
| 10 mM | 0.10 mL | 0.52 mL | 1.04 mL |
| 50 mM | 0.02 mL | 0.10 mL | 0.21 mL |
Calculators
Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Background References
References are publications that support the biological activity of the product.
- Sedrani Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc. 1998 PMID: 9723437
- Galluzzi Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat.Rev.Drug.Discov. 2017 PMID: 28529316
- Lane mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin.Cancer Res. 2009 PMID: 19223496
Product Specific Notices for Everolimus
For research use only
Loading...
Loading...